Total Payments
$9,932
2024 Payments
$568.69
Companies
39
Transactions
359
Medicare Patients
943
Medicare Billing
$246,210
Payment Breakdown by Category
Food & Beverage$5,873 (59.1%)
Gifts$2,583 (26.0%)
Other$931.52 (9.4%)
Education$544.49 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,873 | 324 | 59.1% |
| Gift | $2,583 | 11 | 26.0% |
| Long term medical supply or device loan | $931.52 | 10 | 9.4% |
| Education | $544.49 | 14 | 5.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,179 | 74 | $0 (2024) |
| Allergan, Inc. | $1,227 | 2 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $638.04 | 22 | $0 (2023) |
| Amgen Inc. | $607.43 | 32 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $532.23 | 30 | $0 (2024) |
| Merck Sharp & Dohme LLC | $475.79 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $454.51 | 14 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $298.65 | 18 | $0 (2024) |
| Daiichi Sankyo Inc. | $296.47 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $249.08 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $568.69 | 32 | Rigel Pharmaceuticals, Inc. ($95.30) |
| 2023 | $1,060 | 40 | Novartis Pharmaceuticals Corporation ($206.21) |
| 2022 | $1,738 | 80 | Novartis Pharmaceuticals Corporation ($630.02) |
| 2021 | $1,377 | 64 | Novartis Pharmaceuticals Corporation ($652.42) |
| 2020 | $3,188 | 42 | Novartis Pharmaceuticals Corporation ($1,439) |
| 2019 | $845.58 | 37 | E.R. Squibb & Sons, L.L.C. ($193.89) |
| 2018 | $592.78 | 30 | Janssen Biotech, Inc. ($92.68) |
| 2017 | $562.10 | 34 | E.R. Squibb & Sons, L.L.C. ($119.21) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $14.67 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $9.17 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.75 | General |
| 10/30/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $12.35 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $16.73 | General |
| Category: Oncology / Rare Diseases | ||||||
| 08/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.71 | General |
| Category: Hematology | ||||||
| 06/26/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $17.31 | General |
| 06/18/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Oncology | ||||||
| 05/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 04/23/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Oncology | ||||||
| 04/23/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $6.82 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $19.81 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/28/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $31.88 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 03/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $14.60 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/05/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 258 | 578 | $202,061 | $57,737 |
| 2022 | 3 | 212 | 455 | $159,918 | $49,837 |
| 2021 | 3 | 237 | 623 | $210,073 | $66,881 |
| 2020 | 3 | 236 | 838 | $241,082 | $71,754 |
Total Patients
943
Total Services
2,494
Medicare Billing
$246,210
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 332 | $98,883 | $30,566 | 30.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 109 | $42,965 | $13,588 | 31.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $17,613 | $6,032 | 34.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 79 | $31,100 | $4,763 | 15.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $11,500 | $2,789 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 90 | 190 | $74,327 | $22,275 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 87 | 230 | $68,385 | $22,073 | 32.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $17,206 | $5,490 | 31.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 116 | 403 | $120,818 | $35,813 | 29.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 92 | 191 | $74,848 | $26,128 | 34.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $14,406 | $4,939 | 34.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 130 | 699 | $182,282 | $57,683 | 31.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 74 | 107 | $42,800 | $9,412 | 22.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 32 | 32 | $16,000 | $4,659 | 29.1% |
About Dr. Constance Wash, MD
Dr. Constance Wash, MD is a Medical Oncology healthcare provider based in Las Cruces, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932148384.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Constance Wash, MD has received a total of $9,932 in payments from pharmaceutical and medical device companies, with $568.69 received in 2024. These payments were reported across 359 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($5,873).
As a Medicare-enrolled provider, Wash has provided services to 943 Medicare beneficiaries, totaling 2,494 services with total Medicare billing of $246,210. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Las Cruces, NM
- Active Since 06/04/2006
- Last Updated 11/17/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1932148384
Products in Payments
- KISQALI (Drug) $2,350
- OPDIVO (Biological) $492.07
- KEYTRUDA (Biological) $475.79
- Kyprolis (Drug) $462.68
- IMBRUVICA (Drug) $284.49
- PIQRAY (Drug) $244.72
- MEKINIST (Drug) $227.07
- Stivarga (Drug) $206.73
- TUKYSA (Drug) $186.04
- DARZALEX (Biological) $170.02
- Nubeqa (Drug) $165.35
- ENHERTU (Drug) $161.22
- Rezlidhia (Drug) $158.16
- Tavalisse (Drug) $140.49
- Enhertu (Drug) $135.25
- Vitrakvi (Drug) $127.38
- clonoSEQ (Device) $126.65
- EMPLICITI (Biological) $121.54
- TAGRISSO (Drug) $119.37
- Trodelvy (Drug) $116.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.